Heparanase pretreatment attenuates endotoxin-induced acute lung injury in rats

• Published in: Shock (Augusta, Ga.) Vol. 28; no. 2; pp. 207 - 212
• Main Authors: Bashenko, Yulia, Ilan, Neta, Krausz, Michael M, Vlodavsky, Israel, Hirsh, Mark I
• Format: Journal Article
• Language: English
• Published: United States 01-08-2007
• Subjects: Animals; Cell Line; Drug Synergism; Endotoxins - toxicity; Glucuronidase - therapeutic use; Humans; Lipopolysaccharides - toxicity; Lung - drug effects; Lung - pathology; Male; Rats; Rats, Sprague-Dawley; Respiratory Distress Syndrome, Adult - chemically induced; Respiratory Distress Syndrome, Adult - drug therapy
• ISSN: 1073-2322
• DOI: 10.1097/shk.0b013e3180311d84

A central event of systemic inflammation and septic organ injury is infiltration of tissues with polymorphonuclear neutrophils, likely modulated by the integrity of the extracellular matrix underlying the vascular endothelium. In the present study, the effect of matrix-modifying endoglycosidase (heparanase) on endotoxin (LPS)-induced inflammatory lung injury was investigated in rats. Animals were treated with heparanase or LPS or pretreated with heparanase before LPS injection, and acute lung injury was verified histologically and characterized by analysis of bronchoalveolar lavage fluids. Pretreatment with heparanase attenuated the mortality of animals and preserved the histological structure of the lungs. Furthermore, polymorphonuclear neutrophil accumulation and activation, analyzed by myeloperoxidase release and reactive oxygen species production associated with lung injury, were significantly reduced upon heparanase pretreatment. In addition, heparanase pretreatment elevated the IL-10 levels in the pulmonary compartment. Moreover, results from in vitro experiments have identified monocyte-derived IL-10 as an important mediator used by heparanase to suppress inflammatory reactions. The protective effect of heparanase may indicate a novel therapeutic strategy for sepsis.